| Recruiting | Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2 NCT07225127 | University of Washington | — |
| Active Not Recruiting | A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer NCT04917809 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Afatinib in Advanced Refractory Urothelial Cancer NCT02122172 | University of Chicago | Phase 2 |
| Withdrawn | Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer NCT02252393 | Case Comprehensive Cancer Center | N/A |
| Completed | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointe NCT01846520 | City of Hope Medical Center | N/A |
| Withdrawn | Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and NCT01639521 | University of Southern California | Phase 2 |
| Terminated | Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder NCT01382706 | University of Southern California | Phase 2 |
| Terminated | Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery NCT01108003 | Roswell Park Cancer Institute | N/A |
| Terminated | Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer NCT01118351 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Pazopanib in Treating Patients With Metastatic Urothelial Cancer NCT00471536 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Functi NCT00478361 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both? NCT03174912 | Ankara Training and Research Hospital | Phase 4 |
| Completed | VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium NCT00407485 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium NCT00112905 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract NCT00112671 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma NCT01828736 | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Phase 2 |
| Completed | Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transition NCT00072150 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothe NCT00004856 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Decitabine in Treating Patients With Advanced Solid Tumors NCT00030615 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer NCT00021099 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Celecoxib in Treating Patients With Bladder Cancer NCT00006124 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Completed | Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tra NCT00005831 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gene Therapy in Treating Patients With Advanced Bladder Cancer NCT00003167 | National Cancer Institute (NCI) | Phase 1 |
| No Longer Available | An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer NCT03801278 | Five Prime Therapeutics, Inc. | — |